Hyperplasia News and Research

RSS

Transvaginal ultrasound effective in treating early-stage endometrial cancer

A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type.

17 Oct 2012

Curcumin can inhibit formation of prostate cancer metastases

Powdered turmeric has been used for centuries to treat osteoarthritis and other illnesses. Its active ingredient, curcumin, inhibits inflammatory reactions. A new study led by a research team at Ludwig-Maximilians-Universit-t (LMU) in Munich now shows that it can also inhibit formation of metastases.

13 Oct 2012

MRI method ‘cuts breast cancer false‑positives’

Assessing apparent diffusion coefficients during dynamic contrast-enhanced magnetic resonance imaging may reduce the number of avoidable false‑positive breast cancer results and unnecessary biopsies, show findings published in Radiology.

9 Oct 2012

GW professor to develop blood test for early detection of breast cancer

Today, patients with precancerous lesions, or early-stage breast cancer are usually diagnosed after a mammography screening. This method of detection can lead to false-positives and overtreatment, since mammography cannot determine whether pre-cancerous cells will actually turn into breast cancer. This may all change after Sidney Fu, M.D., professor of medicine at the George Washington School of Medicine and Health Sciences (SMHS), completes his study of early breast cancer detection using novel small RNA (microRNA or miRNA) biomarkers.

5 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

RRM2 may be a facilitating factor in colorectal cancer and UV-induced DNA damage repair

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

20 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

GORE Hybrid Vascular Graft receives CE Mark approval

W. L. Gore & Associates (Gore) has received CE Mark for the GORE Hybrid Vascular Graft. The graft is designed to expand treatment options for optimal outflow by maximizing the number of access sites available.

20 Aug 2012

TAIN project aims to optimise treatment for babies with adrenal insufficiency

Groundbreaking research into rare neonatal diseases, conducted by the University of Sheffield, is set to improve the treatment of babies who lack the stress hormone cortisol.

15 Aug 2012

Risky prenatal use of steroid to prevent intersex, tomboys and lesbians

A new paper just published in the Journal of Bioethical Inquiry uses extensive Freedom of Information Act findings to detail an extremely troubling off-label medical intervention employed in the U.S. on pregnant women to intentionally engineer the development of their fetuses for sex normalization purposes.

3 Aug 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Symptom relief at the core of prostate patient management

More focus should be placed on relieving the most bothersome or “core” symptom for patients with benign prostatic hyperplasia, report Korean researchers.

11 Jul 2012

Prenatal exposure to BPA appears to program uterine estrogen responsiveness in adulthood

Prenatal exposure to bisphenol A, or BPA, a chemical found in many common plastic household items, can cause numerous genes in the uterus to respond differently to estrogen in adulthood, according to a study using a mouse model. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

AUA Foundation introduces It's Time to Talk About OAB campaign

On the heels of the fourth annual World Continence Week, the American Urological Association (AUA) Foundation has launched "It's Time to Talk About OAB," a nationwide education campaign designed to elevate awareness of Overactive Bladder (OAB), a common, yet often untreated condition, as a public health issue.

20 Jun 2012

FDA clears Teleflex’s ARROW PICC with Chloragard technology

Teleflex Incorporated announced today that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chloragard Technology provides antithrombogenic protection for at least 30 days.

22 May 2012

Quest Diagnostics introduces four new tests panels for CAH

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women.

From Quest Diagnostics 19 May 2012

Urologic conditions contribute to major economic burden in the U.S.

Urologic conditions like urinary tract infections, kidney stones, and prostate cancer are a major economic burden on Americans, resulting in health care costs of close to $40 billion annually, according to a newly released national report that charts the demographic and economic impact of urologic diseases in the U.S.

19 May 2012

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

A dose of 10 milligrams (mg) daily of S-equol delivered via a newly developed fermented soy germ-based nutritional supplement is as effective as a standard dose of soy isoflavones at reducing hot flash frequency significantly and is even more effective for relieving muscle and joint pain, according to a peer-reviewed study in US postmenopausal women published in the June Journal of Women's Health, available now as a Fast Track article online ahead of print.

25 Apr 2012